FDA EIR - Abbott Laboratories

**FDA EIR Summary: NOVOCAIN® (Procaine Hydrochloride Injection, USP)**

**Company Name:** Not specified in the provided document.

**Inspection Dates:** Not specified in the provided document.

**Main Violations/Issues:** The document does not explicitly list violations or issues, but it provides detailed information on the composition, pharmacology, and pharmacokinetics of NOVOCAIN® (Procaine Hydrochloride Injection, USP). It emphasizes that these solutions are not intended for spinal, epidural anesthesia, or dental use, suggesting a potential area of concern if used incorrectly.

**Regulatory Framework:** The document outlines the chemical and pharmacological properties of procaine hydrochloride, an ester-type local anesthetic. It details the composition of available solutions, including the presence of acetone sodium bisulfite as an antioxidant and chlorobutanol as an antimicrobial preservative. The solutions are made isotonic with sodium chloride, and the pH is adjusted with sodium hydroxide and/or hydrochloric acid.

**Required Actions:** While specific required actions are not detailed, the document implicitly requires adherence to the intended use of the product, ensuring it is used only for local infiltration and peripheral nerve block, not for spinal, epidural, or dental anesthesia. Proper understanding and application of the pharmacokinetics and pharmacodynamics are crucial to avoid systemic toxicity, which can lead to severe cardiovascular and central nervous system effects.

This summary highlights the critical aspects of NOVOCAIN® as outlined in the document, focusing on its intended use and the importance of adhering to specified guidelines to prevent misuse and potential adverse effects.